Cargando…

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia

While the positive association between automated intact fibroblast growth factor (FGF) 23 measurement kit (Determinar CL FGF23 [CL]) and the former assay (Kainos [KI]), and clinical utility of CL was well established, the clinical performance of Medfrontier FGF23 (MED), which was the manual intact F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Hajime, Miyazaki, Hiromi, Kimura, Takehide, Hoshino, Yoshitomo, Hidaka, Naoko, Koga, Minae, Nangaku, Masaomi, Makita, Noriko, Ito, Nobuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Full Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932357/ https://www.ncbi.nlm.nih.gov/pubmed/36817167 http://dx.doi.org/10.1016/j.bonr.2023.101659

Ejemplares similares

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption
por: Hidaka, Naoko, et al.
Publicado: (2021)

Incidence of ossification of the spinal ligaments in acromegaly patients
por: Hoshino, Yoshitomo, et al.
Publicado: (2022)

Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors
por: Kato, Hajime, et al.
Publicado: (2022)

Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa
por: Kato, Hajime, et al.
Publicado: (2021)

Radiological evaluation of pseudofracture after the administration of asfotase alfa in an adult with benign prenatal hypophosphatasia: A case report
por: Kato, Hajime, et al.
Publicado: (2021)

Machine Learning–Based Prediction of Elevated PTH Levels Among the US General Population
por: Kato, Hajime, et al.
Publicado: (2022)

FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation
por: Takashi, Yuichi, et al.
Publicado: (2019)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)
por: Kinoshita, Yuka, et al.
Publicado: (2018)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations
por: Bosman, Ariadne, et al.
Publicado: (2023)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage
por: Brandenburg, Vincent, et al.
Publicado: (2020)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Nirogacestat and Hypophosphatemia
por: Gudsoorkar, Prakash, et al.
Publicado: (2023)

Osteogenic Differentiation Effect of BMP-9 with Phenamil and Simvastatin on Intact Human Amniotic Epithelial Stem Cells
por: Ahmadi, Armin, et al.
Publicado: (2022)

Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies
por: Makita, Noriko, et al.
Publicado: (2022)

High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats
por: Gravesen, Eva, et al.
Publicado: (2013)

Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
por: Cheng, Qun, et al.
Publicado: (2018)

C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival
por: Chu, Chang, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

Evaluation of a new automated immunoassay for the quantification of anti-Müllerian hormone
por: Lotierzo, Manuela, et al.
Publicado: (2021)

Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein δ
por: Yamaguchi, Junna, et al.
Publicado: (2015)

Tumor-induced hypophosphatemia
por: Mulani, M., et al.
Publicado: (2017)

Hypophosphatemia in cancer patients
por: Adhikari, Shreedhar, et al.
Publicado: (2021)

Serum 25-hydroxyvitamin D measurement: Comparative evaluation of three automated immunoassays
por: Trimboli, Francesca, et al.
Publicado: (2021)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Developmental impairments of craniofacial bone and cartilage in transgenic mice expressing FGF10
por: Yoshioka, Hirotaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_872npsu62rn1g3psvdji5fh8f7